MorphoSys AG (NASDAQ:MOR) Receives $31.93 Average PT from Analysts

Shares of MorphoSys AG (NASDAQ:MOR – Get Rating) have received an average recommendation of “Hold” from the ten brokerages that are presently covering the company, Marketbeat reports. Seven research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $31.93.

Several brokerages have commented on MOR. JMP Securities reaffirmed a “buy” rating and issued a $41.00 price objective on shares of MorphoSys in a research report on Friday, March 18th. Morgan Stanley dropped their price target on MorphoSys from €40.00 ($42.11) to €37.00 ($38.95) and set an “equal weight” rating on the stock in a research report on Friday, May 20th. Berenberg Bank assumed coverage on MorphoSys in a research report on Thursday, March 24th. They set a “buy” rating on the stock. Citigroup reissued a “neutral” rating and set a €31.00 ($32.63) price target on shares of MorphoSys in a research report on Tuesday, March 22nd. Finally, Deutsche Bank Aktiengesellschaft dropped their price target on MorphoSys from €46.00 ($48.42) to €30.00 ($31.58) and set a “hold” rating on the stock in a research report on Tuesday, March 22nd.

Shares of MorphoSys stock opened at $5.12 on Thursday. The stock’s fifty day moving average is $5.32 and its two-hundred day moving average is $6.93. The company has a market capitalization of $701.07 million, a PE ratio of -1.00 and a beta of 1.12. The company has a quick ratio of 3.91, a current ratio of 3.98 and a debt-to-equity ratio of 1.15. MorphoSys has a 52 week low of $4.35 and a 52 week high of $20.47.

Large investors have recently made changes to their positions in the company. Quadrant Capital Group LLC raised its stake in shares of MorphoSys by 79.3% in the fourth quarter. Quadrant Capital Group LLC now owns 4,892 shares of the company’s stock worth $46,000 after purchasing an additional 2,164 shares during the last quarter. Signaturefd LLC grew its holdings in MorphoSys by 118.5% during the fourth quarter. Signaturefd LLC now owns 9,420 shares of the company’s stock worth $89,000 after acquiring an additional 5,108 shares during the period. Capricorn Fund Managers Ltd acquired a new stake in MorphoSys during the first quarter worth about $177,000. Marshall Wace LLP grew its holdings in MorphoSys by 214.2% during the third quarter. Marshall Wace LLP now owns 32,493 shares of the company’s stock worth $382,000 after acquiring an additional 22,151 shares during the period. Finally, Renaissance Technologies LLC acquired a new stake in MorphoSys during the third quarter worth about $607,000. Hedge funds and other institutional investors own 1.81% of the company’s stock.

About MorphoSys (Get Rating)

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.

Featured Articles